The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
ID: ALA1609153
Max Phase: Preclinical
Molecular Formula: C17H25N3O3
Molecular Weight: 319.40
Molecule Type: Small molecule
Associated Items:
Representations Canonical SMILES: CCOC(=O)N1CCC(NCCNC(=O)c2ccccc2)CC1
Standard InChI: InChI=1S/C17H25N3O3/c1-2-23-17(22)20-12-8-15(9-13-20)18-10-11-19-16(21)14-6-4-3-5-7-14/h3-7,15,18H,2,8-13H2,1H3,(H,19,21)
Standard InChI Key: VNRSRVXFGIQMBW-UHFFFAOYSA-N
Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Properties Molecular Weight: 319.40Molecular Weight (Monoisotopic): 319.1896AlogP: 1.63#Rotatable Bonds: 6Polar Surface Area: 70.67Molecular Species: BASEHBA: 4HBD: 2#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 0CX Acidic pKa: CX Basic pKa: 9.65CX LogP: 0.91CX LogD: -1.29Aromatic Rings: 1Heavy Atoms: 23QED Weighted: 0.78Np Likeness Score: -1.21
References 1. PubChem BioAssay data set, 2. Sheffler DJ, Sevel C, Le U, Lovell KM, Tarr JC, Carrington SJ, Cho HP, Digby GJ, Niswender CM, Conn PJ, Hopkins CR, Wood MR, Lindsley CW.. (2013) Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism., 23 (1): [PMID:23200253 ] [10.1016/j.bmcl.2012.10.132 ]